The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Juxtapid
lomitapide mesylate · LOMITAPIDE MESYLATE 30 mg/1 · Capsule · Oral · Pharma Packaging Solutions, LLC dba Tjoapack LLC
NDC 75929-0172-25 · 28 CAPSULE in 1 BOTTLE · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 10122-0430-28) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$2,068.50per unit
middle half $2,037.90–$2,111.38 · 198 plans · Apr 1, 2026
Est. net of rebatesⓘ
$1,241.10–$1,551.38
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
4%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 76%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $59,762.07 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Juxtapid
Regulatory
- Application
- NDA203858
- TE code
- —
- Approval date
- Dec 21, 2012
- Patents / exclusivity
- 12 patents, 6 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NPP | Feb 25, 2029 |
| exclusivity | NPP | Feb 25, 2029 |
| exclusivity | NPP | Feb 25, 2029 |
| exclusivity | NPP | Feb 25, 2029 |
| exclusivity | NPP | Feb 25, 2029 |
| exclusivity | NS | Feb 25, 2029 |
| patent | 12472172 | Jul 29, 2041 |
| patent | 12472172 | Jul 29, 2041 |
| patent | 12472172 | Jul 29, 2041 |
| patent | 12472172 | Jul 29, 2041 |
| patent | 12472172 | Jul 29, 2041 |
| patent | 7932268 | Aug 19, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of lomitapide mesylate (Capsule)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Catalent Pharma Solution, LLC | LOMITAPIDE MESYLATE 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Amryt Pharmaceuticals DAC | LOMITAPIDE MESYLATE 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amryt Pharmaceuticals DAC | LOMITAPIDE MESYLATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Catalent Pharma Solution, LLC | LOMITAPIDE MESYLATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chiesi USA, Inc. | LOMITAPIDE MESYLATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chiesi USA, Inc. | LOMITAPIDE MESYLATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chiesi USA, Inc. | LOMITAPIDE MESYLATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chiesi USA, Inc. | LOMITAPIDE MESYLATE 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chiesi USA, Inc. | LOMITAPIDE MESYLATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Catalent Pharma Solution, LLC | LOMITAPIDE MESYLATE 20 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| Catalent Pharma Solution, LLC | LOMITAPIDE MESYLATE 10 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| Pharma Packaging Solutions, LLC dba Tjoapack LLC | LOMITAPIDE MESYLATE 20 mg/1 | Jul 15, 2026 | Jul 23, 2026 |
| Pharma Packaging Solutions, LLC dba Tjoapack LLC | LOMITAPIDE MESYLATE 30 mg/1 | Jul 15, 2026 | Jul 22, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Juxtapid — NDC 75929-0172-25," retrieved September 3, 2026, https://drugdashboards.com/drug/75929017225.
Free to cite with attribution — see how the data is put together.